China's self-developed human avian influenza vaccine enters Phase II clinical trial

China's self-developed human avian influenza vaccine - "pandemic influenza vaccine", recently approved by the State FoodDrug administration, theadministration, began to enter the second phase of clinical trialsIt is understood that this time approved for clinical research of the pandemic influenza vaccine is divided into two, one is the pandemic influenza virus inactivated vaccine, will be first in the Phase I adult group clinical trial research based on The I-b trial, increase the dose of the vaccine, the age range extended to 1
2to 70
years old, to evaluate the clinical tolerance and safety of different doses of the vaccine in people of all ages; On this basis, the adult group of phase II clinical studies were carried out to further compare theof immunogenicity and safety of different doses of,under different immune procedures,and finally determine theof the immunization dose and immune procedures of the vaccine, andto develop aof the registrationstandard" Pandemic influenza vaccine " was developed by Beijing Kexing Biological Products Co., Ltdand the China Disease Prevention and Control Center "If phase II clinical trials are completed
, means that we have mastered the key core technologies of human avian influenza vaccines," said Zhang Jiansan, deputy general manager of Beijing Kexing Biological Products Co., Ltd At the same time
, with the support of the relevant departments of the state, we are building capacity for vaccine production to ensure that in the event of a pandemic, we can provide an effective vaccine in a timely manner to control the spread of influenza "
human avian influenza vaccine is the national "15" science and technology projects and national major research projects Through this research, China has established a corresponding technology research and development platform, it can not only prepare human avian influenza vaccine to deal with the avian influenza virus caused by the influenza pandemic, but also after the avian influenza virus mutation, according to the rapid vaccine production of the virus, this study reached the international advanced level (
reprinted from "Xinhuanet")